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CASE REPORT
Carbamazepine, hepatotoxicity, organic solvents, and
paints
Kenneth R. Kaufman
Departments of Psychiatry and Neurology, UMDNJ-Robert Wood Johnson Medical School,
125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA
Hepatotoxicity secondary to carbamazepine is a serious condition which can be fatal. However, other concomitant medications
or environmental factors may be the offending agents. In this case report, hepatotoxicity secondary to organic solvents and paints
is described.
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Treatment of bipolar affective disorders has become
more comprehensive during the past decade. Where,
once, lithium was the only mood stabilizing psy-
chotropic, anticonvulsants have become the treatment
of choice for mixed/rapid cycling disorders and first
line agents for classical manias and bipolar depressed
patients1, 2. Blood dyscrasias (neutropenia, thrombo-
cytopenia, anemia) and liver function abnormalities to
the point of frank hepatotoxicity are well-known com-
plications associated with anticonvulsants monitored
by epileptologists3. Furthermore, the fatality rate for
hepatotoxicity associated with carbamazepine is 25%4.
With the advent of anticonvulsants in the treatment of
bipolar disorders, it is critical that similar monitoring
be performed by psychiatrists. What is not appreciated
is the potential for a concomitant chemical, be it phar-
maceutical or environmental, to be the offending agent.
In this case report, organic solvent and paint hepatotox-
icity masquerading as carbamazepine hepatotoxicity is
described.
Case
This patient, a 48 year old white married male, has a
23 year history of bipolar affective disorder5. He first
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Ireland, June 30, 1997.1059–1311/99/040250 + 03 $12.00/0presented with a classic manic cluster, including in-
creased creativity, pressured speech, flight of ideas,
grandiosity, decreased sleep, decreased appetite and
spending sprees which required hospitalization. The
patient responded to lithium and remained symptom
free for 5 years when, after being taken off lithium
for 18 months, he had a recurrent manic episode.
On that occasion he revealed cycling and was hospi-
talized three times within 6 months. Again, he was
stabilized on lithium and was on 1500/1800 mg qd,
when first seen by this physician in 1984. The patient’s
lithium level was 0.7 mEq/l. The same regimen was
maintained through the spring of 1987. Liver func-
tion tests and CBC remained normal between 1984–
1987. When seen on 19/5/87, the patient was in a hy-
pomanic state and clearly escalating. His lithium was
increased to 1800 mg qd with a resultant blood level of
1.1 mEq/l. Haloperidol was titrated up to 20 mg qd
with benztropine prn. Unfortunately, in his increas-
ingly confused state as his manic episode worsened, he
took the benztropine on a regular basis and haloperi-
dol prn. The patient was ultimately hospitalized from
2/6/87–15/7/87 with a complete manic cluster, marked
confusion, and frank delusions. As the patient had
had a lithium breakthrough episode with historical
cycling, the patient was changed to carbamazepine
which was titrated successfully to 200 mg qid. During
the hospitalization, all chemistries were within normal
limits excluding mildly elevated SGPTs—the admis-
sion value was 55 and the discharge value was 58.c© 1999 BEA Trading Ltd
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Table 1: Serial liver enzymes on anticonvulsants with hepatotoxic agents.
Date SGOT <50 SGPT <55 GGT <65 Alkaline phosphatase Anticonvulsant
<140
15/7/87 nl 58 nl nl CBZ
5/8/87 26 37 88 nl CBZ
16/11/87 116 234 296 173 CBZ
23/11/87 109 213 256 149 CBZ
15/12/87 51 112 192 116 CBZ
22/12/87 47 95 196 131 CBZ
29/12/87 41 79 177 130 CBZ
5/1/88 33 63 155 128 CBZ
12/1/88 38 72 160 129 CBZ
19/1/88 32 49 133 118 CBZ
26/1/88 32 35 110 115 CBZ
1/2/88 27 43 108 123 CBZ
18/2/88 28 44 103 118 CBZ
2/3/88 22 31 85 111 CBZ
1/6/88 24 37 84 135 CBZ
22/11/88 23 32 87 122 CBZ
21/2/89 21 25 73 99 CBZ
17/7/90 23 32 79 124 CBZ
10/7/91 28 34 80 119 CBZ
24/9/92 27 31 107 138 CBZ
15/12/93 36 42 113 131 CBZ
29/9/94 21 19 105 87 CBZ
9/5/95 19 19 81 102 CBZ
22/12/95 21 25 93 60 CBZC VPA a
a CBZ, carbamazepine; VPA, valproic acid.The carbamazepine blood level on 200 mg qid was
6.5 mg/l.
As an outpatient following this hospitalization, the
patient remained stable on the carbamazepine regi-
men. The first liver function tests drawn on 5/8/87, or
three weeks after discharge, were all normal exclud-
ing a GGT of 88 (normal is <65). The patient did not
have his next blood work drawn as scheduled, and his
liver function tests drawn on 16/11/87 revealed marked
abnormalities: SGOT 116 (normal is <50), SGPT 234
(normal is <55), GGT 296, and alkaline phosphatase
173 (normal is <140).
The patient had no jaundice, itching, change in the
color of his stool or urine, or loss of appetite. At this
juncture, a critical decision concerning the continuation
of carbamazepine was required. Repeat liver function
tests on 23/11/87 revealed continued significant abnor-
malities; however, the values of all four liver function
tests decreased to 109, 213, 256, and 149, respectively.
This physician pursued an in-depth evaluation of the
patient for any other potential etiology and determined
to continue this psychotropic regimen while closely
monitoring the liver function tests as long as serial
liver function tests continued to decrease. The internist
in concert with a hepatology consultant recommended
discontinuation of the carbamazepine.
The comprehensive history of potential occu-
pational/environmental/medical offending agents re-
vealed that the patient had recently painted his home
prior to the initial transaminase spikes. More impor-
tantly, he had used paint thinner, carbon tetrachloride,organic solvents, and both acrylic and enamel paints
in enclosed areas without ventilation. The other factor
noted was a long-term history of drinking, 6–8 beers
per week.
Hepatitis screen and abdominal ultrasound were
both negative as were extensive chemistries. Absolute
eosinophil counts were always normal. Regardless of
instructions, the patient continued the same alcohol
consumption. As noted in Table 1, all liver enzymes
continued to improve even though the patient remained
on carbamazepine.
During the past nine years, the patient has had further
bipolar episodes requiring increased titration of carba-
mazepine to a maximum dosage of 1600 mg qd with
clonazepam 2 mg qd and risperidone 4–6 mg qd. Ulti-
mately, the patient was initiated on valproic acid with
the intent of changing to valproic acid as monotherapy.
When last seen by this physician on 1/2/96, the patient
was on carbamazepine 1400 mg qd and valproic acid
2250 mg qd with normal liver function tests excluding
a GGT of 93. Repeat hepatitis A/B/C screen remained
negative for prior hepatitis. The patient had continued
alcohol ingestion of 6–8 beers per week.
Discussion
The patient’s liver function abnormalities could have
been secondary to carbamazepine. In that case, the
consequences of marked morbidity, if not fatality, are
significant4, 6, 7. Carbamazepine induced hepatotoxic-
252 K. R. Kaufman
References
1. }Frances, A., Doherty, J. P. and Kuhn, D. A. The expert consen-
sus guideline series—treatment of bipolar disorder. Journal of
Clinical Psychiatry 1996; 57: 1–88.
2. }Post, R. M., Altshuler, L. L., Ketter, T. A., Denicoff, K. and
Weiss, S. R. Antiepileptic drugs in affective illness: clinical
and theoretical implications. Advances in Neurology 1991; 55:
239–277.
3. }Wyllie, E. and Wyllie, R. Routine laboratory monitoring for
serious adverse effects of antiepileptic medications: the con-
troversy. Epilepsia 1991; 32 (Suppl. 5): S74–S79.
4. }Dreifuss, F. E. and Langer, D. H. Hepatic considerations in
the use of antiepileptic drugs. Epilepsia 1987; 28 (Suppl. 2):
S23–529.
5. }American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4th Edition. Washington, DC,
American Psychiatric Association, 1994.
6. }Horowitz, S., Patwardhan, R. and Marcus, E. Hepatotoxic reac-
tions associated with carbamazepine therapy. Epilepsia 1988;
29: 149–154.
7. }Davion, T., Capron, J. P., Andrejak, M., Geoffroy, P., Capron-
Chivrac, D. and Quenum, C. Acute hepatitis due to carba-
mazepine: study of a case and review of the literature. Gas-
troenterologie Clinique et Biologique 1984; 8: 52–56.
8. }Levy, M., Goodman, M. W., Van Dyne, B. J. and Sumner, H. W.
Granulomatous hepatitis secondary to carbamazepine. Annals
of Internal Medicine 1981; 95: 64–65.
9. }Levander, H. G. Granulomatous hepatitis in a patient receiving
carbamazepine. Acta Medica Scandinavica 1980; 208: 333–
335.
10. }Dossing, M., Arlien-Soborg, P., Milling Petersen, L. and
Ranek, L. Liver damage associated with occupational expo-
sure to organic solvents in house painters. European Journal of
Clinical Investigations 1983; 13: 151–157.
11. }Chen, J. D., Wang, J. D., Jang, J. P. and Chen, Y. Y. Exposure
to mixtures of solvents among paint workers and biochemi-
cal alterations of liver function. British Journal of Industrial
Medicine 1991; 48: 696–701.
12. }Sotaniemi, E. A., Sutinen, S., Arranto, A. J. and Pelkonen, R. O.
Liver injury in subjects occupationally exposed to chemicals in
low doses. Acta Medica Scandinavica 1982; 212: 207–215.
13. }Lundberg, I. and Hakansson, M. Normal serum activities of
liver enzymes in Swedish workers with heavy exposure to or-
ganic solvents. British Journal of Industrial Medicine 1985;
42: 596–600.
14. }Toskulkao, C., Nhongsaeng, J. and Glinsukon, T. Potentiation
of carbon tetrachloride induced hepatotoxicity by thinner in-
halation. Journal of Toxicological Sciences 1990; 15: 75–86.ity appears to be immune mediated, presents as an acute
granulomatous hepatitis, responds to drug withdrawal,
and reoccurs with drug rechallenge6–9. In this case, the
transaminase spikes occurred 4 months after initiation
of carbamazepine and the eosinophil count was always
normal. Furthermore, continued treatment with carba-
mazepine did not lead to increased liver dysfunction.
A liver biopsy was not performed in this case since the
liver function tests were improving. The patient’s alco-
hol consumption remained constant before, during and
following the period of elevated transaminases and, as
such, alcohol was not considered to be the etiologic
factor. Without any medical illness or known drug re-
action, the abnormalities were presumed to be directly
caused by paint, paint thinner, carbon tetrachloride and
other organic solvent exposure.
This physician delayed discontinuing carbamazepine
based upon the comprehensive history of other poten-
tially offending agents and the patient’s excellent re-
sponse to this psychotropic. At the same time, serial
liver function tests were performed in addition to ab-
dominal ultrasound and absolute eosinophil count. Had
increasing liver dysfunction, elevated eosinophil count,
or abnormal abdominal ultrasound been noted, the car-
bamazepine would have been immediately discontin-
ued. At that point, a liver biopsy would have been pur-
sued. In such circumstances, this patient would have
then been changed to valproic acid for his bipolar dis-
order. Had this been a patient with epilepsy who was
exquisitely controlled with carbamazepine, a rechal-
lenge at a very low dosage would have been considered.
The literature supports the association between hep-
atotoxicity and exposure to paints and organic sol-
vents10–12. One negative study referred to the inhalation
of non-chlorinated solvents, whereas carbon tetrachlo-
ride was involved in this case13. In another study, the
liver function tests normalized within 6 weeks of dis-
continuation of exposure12. In this case, all liver func-
tion tests were within normal limits excluding GGT
within 9 weeks. Furthermore, paint thinner has been
shown to potentiate carbon tetrachloride hepatotoxic-
ity14. None of the studies addressed exposure without
adequate ventilation.
The patient continued to use paint after the episode
of liver dysfunction, but only when there was adequate
ventilation and he discontinued the use of paint thin-
ner or carbon tetrachloride. He has not shown any fur-
ther transaminase spikes. Even with the addition of val-
proic acid, there has been no change in liver function
tests.
The author concludes that this isolated episode of el-
evated liver function tests was causally related to the
use of paints, paint thinner, carbon tetrachloride, andorganic solvents in enclosed areas without ventilation.
Whether there was a synergistic effect among these
agents and carbamazepine is unknown. The author rec-
ommends monitoring liver function tests in patients on
carbamazepine, while always obtaining a complete his-
tory for any other potentially hepatotoxic agent. Fur-
thermore, the patient on carbamazepine should be ad-
vised that exposure to other hepatotoxic medications or
occupational agents should be as minimal as possible.
Finally, the clinician must always remember that the
true etiology will often masquerade.
